Exclusive Summary

• Backed by highly coveted US-FDA and UK-MHRA GMP certifications with an existing US market approval, ensuring fast-track global access via reliance regulatory pathways.
• Provides full dosage strengths (2.5/5/10mg) as an AHA/ACC-recommended first-line therapy for orthostatic hypotension, a condition with soaring demand due to global aging.
• Leverages a robust Chinese manufacturing supply chain to deliver US-FDA approved quality at highly competitive costs, guaranteeing rapid commercialization and lucrative margins for distributors.